Jun 1 2017 Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)– ...
adjuvant capecitabine trials addressing breast cancer. The. 15-year analysis of OS was scheduled in after completion of chemotherapy whenever cancer was.
FULLTEXT
Feb 5 2022 showed that adjuvant capecitabine following or added to ... chemotherapy for stage III HER2-negative breast cancer patients.
s y ?proof=tNature
Breast cancer patients with residual disease after neoadjuvant chemotherapy and offering a course of adjuvant capecitabine or enrolling the patient in a ...
s ?proof=tConcernant
benefit of adjuvant capecitabine par- ticularly in triple negative breast cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy.
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy.
Mar 20 2018 A total of 173
s w ?origin=ppub
Jul 7 2022 breast cancer and without a pCR after neoadjuvant chemotherapy were ... of capecitabine usage in the neoadjuvant and adjuvant settings ...
Phase III trial of adjuvant Capecitabine after standard neo−/adjuvant chemotherapy in patients with early triple-negative breast Cancer (GEICAM/. 2003-
s y
Jun 5 2020 breast cancer (BC) patients with no pathological complete response after neoadjuvant che- motherapy (NAC). The benefit of adjuvant ...